Burkitt Lymphoma: Diagnosis, Prognosis, Symptoms, and Treatments

What Is Burkitt Lymphoma?

Burkitt lymphoma is an aggressive form of B-cell non-Hodgkin lymphoma. B lymphocytes normally help the immune system recognize infections and produce antibodies. In Burkitt lymphoma, genetic changes push a B cell into uncontrolled growth. A rearrangement involving the MYC gene is a defining molecular feature in most cases, essentially leaving the cell’s growth switch stuck in the “on” position.

The disease may involve lymph nodes, the abdomen, intestines, jaw or facial bones, bone marrow, ovaries, kidneys, or the central nervous system. When a large amount of lymphoma is found in the blood or bone marrow, clinicians may also use the term Burkitt leukemia. These are not entirely separate diseases but different presentations along the same biological spectrum.

The Three Clinical Forms

Endemic Burkitt lymphoma occurs mainly in equatorial Africa and frequently affects the jaw or facial bones. It has a strong association with Epstein-Barr virus, commonly called EBV.

Sporadic Burkitt lymphoma occurs worldwide, including in the United States. It commonly presents as a rapidly enlarging abdominal mass and may involve the bowel.

Immunodeficiency-associated Burkitt lymphoma develops in people whose immune systems are weakened, including some people living with HIV and recipients of organ transplants. In people with HIV, Burkitt lymphoma is considered an AIDS-defining cancer.

Sources: NCI, SEER, NIH/NCBI, CDC, and NIH HIV ClinicalInfo.

Burkitt Lymphoma Symptoms

Burkitt lymphoma symptoms often develop suddenly and worsen quickly. The exact pattern depends on where the cancer is growing, so two patients may have very different opening scenes.

Common General Symptoms

• Rapidly enlarging, usually painless lymph nodes
• Unexplained fever
• Drenching night sweats
• Unintentional weight loss
• Marked fatigue or weakness
• Reduced appetite

Fever, night sweats, and unexplained weight loss are sometimes called “B symptoms.” They are not unique to Burkitt lymphoma, but their presence can help doctors assess the extent and behavior of a suspected lymphoma.

Abdominal and Digestive Symptoms

Sporadic Burkitt lymphoma frequently involves the abdomen. Possible signs include belly pain, visible swelling, nausea, vomiting, constipation, diarrhea, gastrointestinal bleeding, or feeling full after eating only a small amount.

A tumor affecting the bowel can occasionally cause an obstruction, perforation, or intussusception, in which one part of the intestine slides into another. These complications may cause severe pain, repeated vomiting, bloody stool, abdominal tenderness, or an inability to pass stool or gas.

Jaw and Facial Symptoms

Jaw or facial swelling is more characteristic of endemic Burkitt lymphoma but can occur in other forms. Patients may notice loose teeth, facial asymmetry, dental discomfort, or a mass that appears to be growing unusually fast.

Bone Marrow Symptoms

When lymphoma cells enter the bone marrow, they can crowd out normal blood-cell production. This may lead to:

• Anemia, causing fatigue, dizziness, or shortness of breath
• Low white blood cell counts, increasing infection risk
• Low platelet counts, causing bruising or bleeding

Central Nervous System Symptoms

If Burkitt lymphoma affects the brain, spinal cord, or surrounding fluid, symptoms may include persistent headaches, vomiting, confusion, facial weakness, seizures, balance problems, numbness, or weakness in an arm or leg.

When Symptoms Need Immediate Attention

Rapidly increasing swelling, severe abdominal pain, repeated vomiting, breathing difficulty, new weakness, confusion, seizures, reduced urination, or unusual bleeding should be treated as urgent. Burkitt lymphoma is not a “let’s see how it looks next month” condition. Fast evaluation matters.

Sources: Mayo Clinic, Cleveland Clinic, NCI, and LLS.

How Burkitt Lymphoma Is Diagnosed

A diagnosis usually begins with a medical history and physical examination, but symptoms alone cannot confirm Burkitt lymphoma. Several infections, inflammatory conditions, and other lymphomas can look similar. The decisive step is obtaining adequate tissue for expert laboratory review.

Physical Examination and Medical History

A doctor will check for enlarged lymph nodes, abdominal swelling, an enlarged liver or spleen, facial masses, and neurological abnormalities. The medical history may cover when symptoms began, how quickly a mass has grown, recent infections, immune-system conditions, medications, organ transplantation, and HIV risk factors.

Biopsy and Pathology Testing

An excisional biopsy, core-needle biopsy, or biopsy of an involved organ may be used, depending on the tumor’s location. Fine-needle aspiration alone often does not provide enough tissue to classify an aggressive lymphoma reliably.

Under the microscope, Burkitt lymphoma may show a classic “starry-sky” pattern. The stars are macrophages clearing away cellular debris among densely packed lymphoma cells. It looks rather poetic for something so unwelcome.

Pathologists also use immunohistochemistry and flow cytometry. Typical cells express B-cell markers such as CD19, CD20, and CD79a, along with germinal-center markers such as CD10 and BCL6. The Ki-67 proliferation index is usually extremely high, reflecting how rapidly the cells are dividing.

Fluorescence in situ hybridization, or FISH, helps identify a MYC rearrangement. Additional genetic testing may be needed to distinguish classic Burkitt lymphoma from other high-grade B-cell lymphomas that can resemble it under the microscope.

Blood Tests

Testing commonly includes:

• A complete blood count
• Kidney and liver function tests
• Electrolyte measurements
• Uric acid, phosphate, and calcium levels
• Lactate dehydrogenase, or LDH

LDH may rise when there is a large amount of rapidly growing lymphoma and is often used in risk assessment. Screening for HIV, hepatitis B, and other infections may also affect treatment planning, particularly when rituximab or intensive chemotherapy is expected.

Imaging Tests

PET/CT or CT imaging helps map the location and extent of disease. Imaging may reveal tumors in the abdomen, lymph nodes, bones, kidneys, ovaries, or other organs. MRI may be used when doctors need a closer look at the brain, spine, or a particular anatomical area.

Bone Marrow Biopsy and Lumbar Puncture

A bone marrow aspiration and biopsy may be performed to determine whether lymphoma cells have entered the marrow. A lumbar puncture can check the cerebrospinal fluid for malignant cells.

Because Burkitt lymphoma has a meaningful risk of spreading to the central nervous system, evaluation and preventive CNS-directed treatment are commonly built into the initial treatment plan.

Staging and Risk Classification

Children are often classified with pediatric systems such as the St. Jude or Murphy approach, while adults may be described with Lugano or Ann Arbor staging. In practice, treatment intensity is frequently determined by risk features rather than a stage number alone.

Important considerations include tumor size, LDH level, bone marrow or CNS involvement, whether an intestinal mass was completely removed, organ function, and the patient’s general health.

Sources: Mayo Clinic, LLS, SEER, NCI pediatric and adult PDQ, and NIH/NCBI.

Burkitt Lymphoma Prognosis

The phrase “fast-growing cancer” understandably sounds terrifying. Yet Burkitt lymphoma is also one of the clearest examples of an aggressive cancer that can be highly curable. Outcomes are generally strongest in children and younger adults, but effective treatment is possible across a wide age range when therapy is selected carefully and supported well.

For children and teenagers with limited-stage Burkitt lymphoma, long-term survival is commonly above 90%. Advanced pediatric disease is also frequently curable with contemporary risk-adapted therapy.

In a National Cancer Institute study of adults treated with dose-adjusted EPOCH-R, overall survival was 87%. Low-risk participants had especially favorable outcomes, although results from a clinical study cannot predict exactly how every patient will respond.

Survival figures vary among studies because patients differ in age, disease burden, overall health, treatment regimen, HIV status, and access to specialized care. Statistics describe groups of people, not an expiration date stamped on one person’s chart.

Factors That Can Affect Outlook

• Age and general health
• How quickly effective treatment begins
• LDH level and total tumor burden
• Whether the bone marrow is involved
• Whether the central nervous system is involved
• Kidney, liver, or other organ function at diagnosis
• Response to the first treatment cycles
• Whether the disease is newly diagnosed, refractory, or relapsed

Relapsed or treatment-resistant Burkitt lymphoma is much harder to cure than newly diagnosed disease. That is one reason the first treatment plan should be designed by a team experienced with aggressive lymphomas rather than assembled casually from a generic lymphoma playbook.

Sources: American Cancer Society, NCI adult trial, NCI PDQ, and Blood real-world study.

Burkitt Lymphoma Treatments

Burkitt lymphoma usually requires treatment soon after diagnosis and medical stabilization. Watchful waiting is not appropriate. The core strategy combines multiple chemotherapy drugs, frequently with the anti-CD20 monoclonal antibody rituximab, plus treatment or prevention of lymphoma in the central nervous system.

Intensive Combination Chemotherapy

Regimens differ by age, risk group, treatment center, and organ function. Examples used in adults include dose-adjusted EPOCH-R, CODOX-M/IVAC, and hyper-CVAD-based therapy. Children and adolescents often receive pediatric LMB- or BFM-style risk-adapted protocols.

These regimens combine several drugs in carefully timed cycles because Burkitt lymphoma cells divide so quickly. Depending on the protocol, medications may include cyclophosphamide, vincristine, doxorubicin, etoposide, methotrexate, cytarabine, ifosfamide, and corticosteroids.

Some treatment schedules require hospitalization, while others allow portions to be administered as an outpatient. The “best” regimen is not automatically the one with the most intimidating acronym. It is the regimen most likely to cure the disease while remaining safe and deliverable for that patient.

Rituximab

Rituximab targets CD20, a protein commonly found on Burkitt lymphoma cells. It is frequently added to chemotherapy and has improved outcomes in pediatric and adult B-cell lymphoma studies.

Before receiving rituximab, patients are generally screened for hepatitis B because the treatment can reactivate the virus in people with current or previous infection. Infusion reactions may also occur, particularly during the first dose, so patients are monitored closely.

Central Nervous System Treatment

Even when no lymphoma cells are detected in the spinal fluid, CNS prophylaxis is commonly included. Methotrexate and cytarabine may be administered into the cerebrospinal fluid, at high systemic doses, or through a combination of both approaches.

Patients with confirmed CNS involvement usually require a more intensive CNS-directed plan. Omitting this part of treatment would give the lymphoma an escape route, and no one wants to leave the back door unlocked.

Preventing Tumor Lysis Syndrome

When chemotherapy destroys large numbers of cancer cells rapidly, their contents can flood the bloodstream. This may disrupt potassium, phosphate, calcium, uric acid, kidney function, and heart rhythm. The complication is known as tumor lysis syndrome.

Prevention may include intravenous fluids, frequent blood tests, close urine monitoring, allopurinol, or rasburicase. High-risk patients are often monitored in the hospital when treatment begins. This is one situation in which boringly frequent laboratory checks are excellent news: boring can be lifesaving.

Supportive Care

Because chemotherapy suppresses bone marrow and immune function, patients may need antibiotics, antiviral medicines, growth-factor support, blood transfusions, platelet transfusions, anti-nausea medication, pain control, and nutritional assistance.

Fever during chemotherapy can signal a serious infection and should be reported immediately according to the care team’s instructions. Patients should not simply take a fever reducer, crawl back under the blankets, and hope the thermometer becomes more cooperative.

Fertility preservation should be discussed before treatment when time and clinical stability permit. Options vary by age, sex, treatment urgency, and the medications being considered.

For people living with HIV, lymphoma therapy and antiretroviral treatment are coordinated to control both conditions while reducing drug interactions and infection risks.

Surgery and Radiation Therapy

Surgery is mainly used to obtain a biopsy or manage complications such as bowel obstruction or perforation. Removing a visible mass does not eliminate microscopic lymphoma elsewhere, so systemic chemotherapy remains essential.

Radiation therapy is uncommon in first-line Burkitt lymphoma treatment. It may occasionally be considered for selected complications or areas that do not respond adequately to systemic therapy.

Treatment for Relapsed or Refractory Disease

There is no single universally preferred salvage approach. Options may include rituximab-based combination chemotherapy, high-dose therapy with stem cell transplantation for selected patients whose disease responds, or enrollment in a clinical trial.

Cellular therapies and newer immune-based treatments are being investigated, but their role in Burkitt lymphoma is still evolving. A second opinion at a major lymphoma center may be particularly valuable when the disease does not respond to initial therapy or returns afterward.

Sources: NCI PDQ, ACS, NCI rituximab study, FDA rituximab label, NIH HIV ClinicalInfo, and LLS.

Possible Treatment Side Effects

Side effects depend on the exact regimen, dose, and patient. Common problems may include:

• Fatigue
• Nausea or vomiting
• Mouth sores
• Diarrhea or constipation
• Hair loss
• Low blood-cell counts
• Increased infection risk
• Easy bruising or bleeding
• Changes in taste or appetite

Certain medicines can also affect the heart, nerves, kidneys, liver, bladder, or fertility. Doctors adjust doses and supportive treatment according to laboratory results, side effects, infections, and how quickly blood counts recover.

Patients should receive clear instructions about whom to call and which symptoms cannot wait. Fever, shortness of breath, uncontrolled vomiting, severe diarrhea, confusion, chest pain, reduced urination, unusual bleeding, or rapidly worsening weakness require prompt medical guidance.

Side-effect management is not an optional comfort upgrade. Maintaining hydration, controlling nausea, treating infections early, protecting nutrition, and preserving chemotherapy timing can influence whether curative treatment is completed safely.

Sources: LLS side-effect guidance, Mayo Clinic, and FDA rituximab labeling.

Follow-Up After Treatment

After therapy, the oncology team checks for remission, treatment complications, and signs that the lymphoma has returned. Follow-up may include physical examinations, blood counts, chemistry tests, and imaging when clinically appropriate.

The schedule is usually most intensive during the early years, when relapse is more likely, and then becomes less frequent. Patients should report new lumps, persistent fever, unexplained weight loss, night sweats, abdominal swelling, neurological symptoms, or other concerning changes between appointments.

Survivorship care also matters. Children may need long-term monitoring of growth, learning, heart health, fertility, and other late effects. Adults may need attention to cardiovascular risk, neuropathy, fertility, emotional health, and return-to-work planning.

A written treatment summary should include the diagnosis, pathology findings, chemotherapy drugs and doses, spinal treatments, complications, and recommended follow-up. It can save future clinicians from having to play medical detective with a stack of mysterious records.

Sources: NCI childhood NHL PDQ, LLS, and Mayo Clinic.

Questions to Ask the Cancer Care Team

• Has the biopsy been reviewed by an expert hematopathologist?
• Was a MYC rearrangement confirmed?
• Were other high-grade B-cell lymphomas excluded?
• Is the bone marrow or central nervous system involved?
• Which risk group applies, and why?
• Which chemotherapy regimen is recommended?
• Will treatment require hospitalization?
• How will tumor lysis syndrome be prevented?
• Which symptoms require an immediate hospital visit?
• Should fertility preservation be discussed before treatment?
• Is a second opinion or clinical trial appropriate?

Practical Experience: What Patients and Families Often Learn

The following perspective is a composite of practical lessons commonly encountered during aggressive lymphoma care, not the story of one identifiable patient. The first lesson is that diagnosis can feel strangely rushed. A person may go from “this stomach pain is annoying” to scans, a biopsy, and hospital admission within days. That speed can be frightening, but it usually reflects the biology of Burkitt lymphoma and the need to act efficientlynot carelessness by the medical team.

Families often discover that the opening phase is as much about preventing complications as delivering chemotherapy. Nurses may measure fluid intake, urine output, weight, and blood pressure repeatedly. Blood may be drawn several times a day. Patients sometimes wonder why everyone is so fascinated by potassium and uric acid. The answer is tumor lysis syndrome: when treatment works quickly, the body needs help processing the remains of destroyed cancer cells.

A second lesson is that treatment calendars are complicated. A protocol may include infusion days, spinal treatments, rest periods, growth-factor injections, blood-count checks, and strict rules for calling the hospital. Keeping a shared notebook or phone document helps. Record medications, temperatures, symptoms, questions, and contact numbers. During a stressful week, memory is about as dependable as a shopping cart with one wobbly wheel.

Nutrition can also become a moving target. Some days, normal meals work; on others, nausea, mouth sores, or altered taste make eating difficult. Patients often do better with small portions, bland protein-rich foods, cold drinks, soups, smoothies, or whatever the oncology dietitian approves. Food safety becomes important during periods of low immunity. The goal is not a perfect wellness-menu performanceit is maintaining hydration, calories, and strength safely.

Caregivers learn to distinguish expected discomfort from warning signs. Fatigue and hair loss may be anticipated. Fever, breathing trouble, confusion, uncontrolled vomiting, severe abdominal pain, or reduced urination are different; they deserve immediate contact with the oncology team. Having written temperature thresholds, emergency instructions, and an after-hours telephone number reduces hesitation when everyone is tired and worried.

Emotionally, the experience can be disorienting because Burkitt lymphoma compresses decisions into a short window. Patients may not have time to “feel ready.” A useful approach is to divide the journey into the next manageable step: confirm pathology, prevent tumor lysis, complete the current cycle, recover blood counts, and then reassess.

Psychological support, child-life specialists, social workers, school coordinators, and financial navigators are not decorative extras. They help keep daily life functioning while the medical team fights the disease. Caregivers also need sleep, meals, transportation backups, and permission to accept help instead of attempting a one-person superhero performance.

Finally, remission can bring joy mixed with anxiety. Every ache may briefly feel suspicious. Follow-up appointments can reactivate fear even when tests are reassuring. A survivorship plan, realistic expectations about recovery, and permission to request mental-health support can make the transition easier. Finishing treatment is a major milestone, but recovery is a process rather than a light switch.

Patients may also need guidance about returning to school or work, rebuilding physical stamina, dental care, travel, vaccines, and infection precautions. These decisions should be individualized because immune recovery does not follow exactly the same timetable for everyone.

Conclusion

Burkitt lymphoma is exceptionally fast-growing, so rapid diagnosis and treatment are essential. Confirmation requires a properly handled biopsy, expert pathology, molecular testing, and staging that checks the bone marrow and central nervous system when appropriate.

Treatment usually combines intensive multi-drug chemotherapy, rituximab, CNS-directed therapy, tumor lysis prevention, and meticulous supportive care. Surgery has a limited role, while radiation is reserved for selected circumstances.

Despite its aggressive behavior, newly diagnosed Burkitt lymphoma can often be cured, especially when treatment begins promptly at a center experienced with high-grade lymphomas. Prognosis depends on age, tumor burden, organ function, marrow or CNS involvement, and response to treatment.

Anyone experiencing rapidly worsening swelling, abdominal symptoms, neurological changes, or unexplained systemic symptoms should seek medical evaluation rather than trying to outwait the problem. Burkitt lymphoma moves quickly, and the medical response should move quickly too.